Acute Respiratory Distress Syndrome Treated With Awake Extracorporeal Membrane Oxygenation in a Patient With COVID-19 Pneumonia

Li, Tong; Yin, Peng-Fei; Li, Ang; Shen, Maxwell R

doi:10.1053/j.jvca.2020.11.017

Cited by 12 publications

(13 citation statements)

References 16 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also did not assess factors potentially preventing IFD. One could speculate that the incidence of IFD is lower in patients on awake ECMO with a single dual-lumen cannula, as there is only one vascular access site and these patients are less sedated and potentially self-feeding [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Invasive Fungal Diseases on Survival under Veno-Venous Extracorporeal Membrane Oxygenation for ARDS

Poth

Schewe

Putensen

et al. 2022

JCM

View full text Add to dashboard Cite

Objective: To assess the incidence and significance of invasive fungal diseases (IFD) during veno-venous (VV) ECMO support for acute respiratory distress syndrome (ARDS). Methods: Retrospective analysis from January 2013 to April 2021 of all ECMO cases for ARDS at a German University Hospital. In patients with IFD (IFD patients), type of IFD, time of IFD, choice of antifungal agent, duration, and success of therapy were investigated. For comparison, patients without IFD (non-IFD patients) were selected by propensity score matching using treatment-independent variables (age, gender, height, weight, and the Sequential Organ Failure Assessment (SOFA) score at ICU admission). Demographics, hospital and ICU length of stay, duration of ECMO therapy, days on mechanical ventilation, prognostic scores (Charlson Comorbidity Index (CCI), Therapeutic Intervention Scoring System (TISS), and length of survival were assessed. Results: A total of 646 patients received ECMO, 368 patients received VV ECMO. The incidence of IFD on VV ECMO was 5.98%, with 5.43% for Candida bloodstream infections (CBSI) and 0.54% for invasive aspergillosis (IA). In IFD patients, in-hospital mortality was 81.8% versus 40.9% in non-IFD patients. The hazard ratio for death was 2.5 (CI 1.1–5.4; p: 0.023) with IFD. Conclusions: In patients on VV ECMO for ARDS, about one in 17 contracts an IFD, with a detrimental impact on prognosis. Further studies are needed to address challenges in the diagnosis and treatment of IFD in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Invasive Fungal Diseases on Survival under Veno-Venous Extracorporeal Membrane Oxygenation for ARDS

Poth

Schewe

Putensen

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“… 46 , 47 , 48 These objectives, as recently highlighted, should be pursued even in patients with COVID‐19 on veno‐venous ECMO support. 49 , 50 Several factors contribute to maintaining patients conscious and not intubated, such as the severity and etiology of the respiratory failure, the initial patient’s conditions, the experience of the multidisciplinary team. Certain technical measures (shown in Table 1 ), such as the choice of the device, type of cannulae, and site of cannulation, play a crucial role when implementing an efficient rehabilitation and psychological support program.…”

Section: Methodsmentioning

confidence: 99%

Extracorporeal membrane oxygenation and rehabilitation in patients with COVID‐19: A scoping review

Polastri¹,

Swol²,

Loforte³

et al. 2021

Artificial Organs

View full text Add to dashboard Cite

Background and purpose The coronavirus diseases 2019 (COVID‐19) pandemic posed severe difficulties in managing critically ill patients in hospital care settings. Extracorporeal membrane oxygenation (ECMO) support has been proven to be lifesaving support during the SARS‐CoV‐2 outbreak. The purpose of this review was to describe the rehabilitative treatments provided to patients undergoing ECMO support during the COVID‐19 pandemic. Methods We searched PubMed and Scopus for English‐language studies published from the databases’ inception until June 30, 2021. We excluded editorials, letters to the editor, and studies that did not describe rehabilitative procedures during ECMO support. We also excluded those articles not written in English. Results A total of 50 articles were identified. We ultimately included nine studies, seven of which were case reports. Only two studies had more than one patient; an observational design analyzing the clinical course of 19 patients and a case series of three patients. Extracorporeal support duration varied from 9 to 49 days, and the primary indication was acute respiratory distress syndrome COVID‐19‐related. Rehabilitative treatment mainly consisted of in‐bed mobilization, postural transfers (including sitting), and respiratory exercises. After hospital discharge, patients were referred to rehabilitation facilities. Physiotherapeutic interventions provided during ECMO support and after its discontinuation were feasible and safe. Conclusion The physiotherapeutic treatment of patients undergoing ECMO support includes several components and must be provided in a multidisciplinary context. The optimal approach depends on the patient’s status, including sedation, level of consciousness, ECMO configuration, types of cannulas, and cannulation site.

show abstract

“…A total of 178 studies were found to have reported IFNα treatment for COVID-19 (Supplemental 2). [13] , [17] , [19] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , …”

Section: Comprehensive Review Of the Literature On The Safety And Efficacy Of Interferon Alpha Treatment In Covid-19 Patientsunclassified

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Lu¹,

Feng²,

Yu³

et al. 2022

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1 st , 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.

show abstract

Acute Respiratory Distress Syndrome Treated With Awake Extracorporeal Membrane Oxygenation in a Patient With COVID-19 Pneumonia

Cited by 12 publications

References 16 publications

Impact of Invasive Fungal Diseases on Survival under Veno-Venous Extracorporeal Membrane Oxygenation for ARDS

Impact of Invasive Fungal Diseases on Survival under Veno-Venous Extracorporeal Membrane Oxygenation for ARDS

Extracorporeal membrane oxygenation and rehabilitation in patients with COVID‐19: A scoping review

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Contact Info

Product

Resources

About